Group items tagged

The South Korean pharmaceutical industry is highly fragmented, with almost all the domestic pharmaceutical companies having a strong portfolio of generic products rather than expensive, branded drugs. An increase in insurance coverage, an ageing population and favorable government initiatives are expected to drive future growth in the pharmaceutical industry in South Korea. Improved intellectual property rights, changing demographics and government support have contributed towards making the South Korean pharmaceutical industry attractive for MNCs.

Partnerships, Licensing, Investments and M&A Deals and Trends for January 2014 in Pharmaceuticals report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in July 2013.

Taiwan's pharmaceutical market was worth USD 4.4 billion in 2012 having grown at a CAGR of 2.9%. It is estimated to reach USD 5.5 billion by 2018, growing at a CAGR of 3.9%. Although the size of the market is small compared with other growing markets in Asia, it is expected to provide a market entry point for companies wishing to launch their products in other larger markets.

Analysis of leukemia business development enables tracking cutting edge companies, therapies and new technologies. Analysis of key areas of pharmaceutical R&D helps identify emerging leukemia products. The tool is designed in a way to assist in finding right partners, optimizing licensing deals and choosing projects that give the best competitive advantage.